Case Presentations (January 25, 2021)
This event has passed and can no longer be viewed
This event was presented live or live-streamed and has not been designated for on-demand presentation.
This Breast Tumor Board session will take place on Monday, January 25, 2021 at 7:00 A.M. Attendance for this session will only be available through Zoom.
Activity Information
Needs Statement
Medical oncologists, surgical oncologists, plastic surgeons, pathologists, radiologists, radiation oncologists, internists, general surgeons, and genetic counselors need to receive regular updates on the continually evolving advances in breast cancer management. The tumor board aims to increase the knowledge of learners by using a multidisciplinary case approach and follow-up recommendations to enhance the quality of breast cancer care and to improve patient outcomes.
Educational Objectives
At the conclusion of the sessions, the participants should be able to:
- Discuss the evolution of the role of surgery and radiation in the local management of breast cancer.
- Identify the indications for germline genetic testing and incorporate the results in breast cancer management.
- Utilize FDA-approved targeted therapy and immuno-oncology agents for the various types of breast cancer.
Target Audience
Professional Categories
- Physicians
- Medical Students
- Fellows
- Residents
- Nurses
- Other Health Professionals
Specialties
- Internal Medicine
- Medical Genetics and Genomics
- Nuclear Medicine
- Obstetrics and Gynecology
- Pathology
- Pathology
- Plastic Surgery
- Radiology
- Surgery
- Thoracic Surgery
Interest Groups
- Hospital Medicine
Accreditation/Credit Designation
Baylor College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Baylor College of Medicine designates this enduring material activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Activity Director
Disclosure Policy
Baylor College of Medicine (BCM) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education (CME) for physicians. BCM is committed to sponsoring CE activities that are scientifically based, accurate, current, and objectively presented.
In accordance with the ACCME Standards for Commercial Support, BCM has implemented a mechanism requiring everyone in a position to control the content of an educational activity (i.e., directors, planning committee members, faculty) to disclose any relevant financial relationships with commercial interests (drug/device companies) and manage/resolve any conflicts of interest prior to the activity. Individuals must disclose to participants the existence or non-existence of financial relationships at the time of the activity or within 24 months prior.
In addition, BCM has requested activity faculty/presenters to disclose to participants any unlabeled use or investigational use of pharmaceutical/device products; to use scientific or generic names (not trade names) in referring to products; and, if necessary to use a trade name, to use the names of similar products or those within a class. Faculty/presenters have also been requested to adhere to the ACCME's validation of clinical content statements.
BCM does not view the existence of financial relationships with commercial interests as implying bias or decreasing the value of a presentation. It is up to participants to determine whether the relationships influence the activity faculty with regard to exposition or conclusions. If at any time during this activity you feel that there has been commercial/promotional bias, notify the Activity Director or Activity Coordinator. Please answer the questions about balance and objectivity in the activity evaluation candidly.
All of the relevant financial relationships listed for these individuals have been mitigated.
Disclosures
The following individual(s) has/have reported financial or other relationship(s) with commercial entities whose products/services may relate to the educational content of this activity:
Presenters
-
-
Julie Rani Nangia, M.D.
Assistant Professor
Baylor College of Medicine
Disclosure:
- Advisory Committee Membership: Novartis
- Consultancy: Guidepoint
-
C. Kent Osborne, M.D.
Professor and Director
Baylor College of Medicine
Disclosure:
- Advisory Committee Membership: Genentech; Tolmar Pharma
- Review Panel Membership: Eli Lilly
- Honorarium Recipient: Eli Lilly; Genentech; Tolmar Pharma
- Ownership Interests (stock, stock options, excluding diversified mutual funds): Genetex
-
Maryam Nemati Shafaee, M.D., MPH
Assistant Professor
Baylor College of Medicine
Disclosure:
- Research Support: Mirati Pharmaceuticals
Activity Director
-
Julie Rani Nangia, M.D.
Assistant Professor
Baylor College of Medicine
Disclosure:
- Advisory Committee Membership: Novartis
- Consultancy: Guidepoint
Planning Committee Members
-
Kellen S. Carril, M.D.
Radiology Resident
Baylor College of Medicine
Disclosure:
Nothing to disclose.
-
-
Michelle S Ludwig, MD, MPH, PhD
Associate Professor
Baylor College of Medicine
Disclosure:
Nothing to disclose.
-
Chandandeep Nagi, M.D.
Associate Professor
Baylor College of Medicine
Disclosure:
Nothing to disclose.
-
Mothaffar Fahed Rimawi, M.D.
Professor
Baylor College of Medicine
Disclosure:
- Research Support: Genentech; Pfizer
- Consultancy: Daiichi Sankyo; Macrogenics; Seattle Genetics
-
-
Karla Sepulveda, M.D.
Associate Professor
Baylor College of Medicine
Disclosure:
Nothing to disclose.
-
Eric J. Silberfein, M.D.
Associate Professor
Baylor College of Medicine
Disclosure:
Nothing to disclose.
-
Alastair Thompson, BSc (Hons), MBChB, MD, FRCS (Ed)
Professor and Chief, Section of Breast Surgery
Baylor College of Medicine
Disclosure:
Nothing to disclose.
-
Sebastian Winocour, M.D., M.Sc., F.A.C.S.
Assistant Professor of Surgery
Baylor College of Medicine
Disclosure:
Nothing to disclose.
Health Topics
Presenters: